EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase I)Klinische Studie (Phase II)

Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer

Xiuning Le, Tae Min Kim iD, Herbert H Loong iD, Arsela Prelaj, Boon Cher Goh, Lin Li, Yong Fang, Shun Lu, Xiaorong Dong, Lin Wu, Yuki Shinno, Gennaro Daniele iD und 18 weitere

New England Journal of Medicine · 06.11.2025 · 393 (18) · 1819-1832

DOI: 10.1056/nejmoa2511065 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift New England Journal of Medicine, erschienen am 06.11.2025. Verfasst von Xiuning Le und 29 weiteren Autor:innen. Beteiligte Einrichtung: M.D. Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsErb-b2 Receptor Tyrosine KinasesTyrosine Kinase InhibitorsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutationProgression-Free SurvivalTime FactorsDiarrheaNeoplasm StagingAdministration, Oral

Substanzen

Antineoplastic AgentsErb-b2 Receptor Tyrosine KinasesTyrosine Kinase InhibitorsERBB2 protein, human

Autor:innen und Institutionen

  • M.D. Anderson Cancer Center, Houston.
  • Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
  • Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong.
  • Phase 1 Clinical Trial Center, Chinese University of Hong Kong, Hong Kong.
  • Oncologia Medica Toracica Dipartimento, Fondazione IRCCS-Istituto Nazionale dei Tumori, Milan.
  • Department of Hematology-Oncology, National University Cancer Institute, Singapore.

ORCID-Profile: Tae Min Kim, Herbert H Loong, Gennaro Daniele

Förderung

  • Bayer

Zitieren

APA

Le, X., Kim, T. M., Loong, H. H., Prelaj, A., Goh, B. C., Li, L., Fang, Y., Lu, S., Dong, X., Wu, L., Shinno, Y., Daniele, G., Yang, T. Y., Kim, H. R., Ruiter, G., Zhao, J., Novello, S., Miao, L., Jänne, P. A., …, & SOHO-01 Investigators (2025). Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine, 393(18), 1819-1832. https://doi.org/10.1056/nejmoa2511065

Vancouver

Le X, Kim TM, Loong HH, Prelaj A, Goh BC, Li L, et al. Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2025;393(18):1819-1832. doi:10.1056/nejmoa2511065

BibTeX
@article{Le2025,
  author = {Le, Xiuning and Kim, Tae Min and Loong, Herbert H and Prelaj, Arsela and Goh, Boon Cher and Li, Lin and Fang, Yong and Lu, Shun and Dong, Xiaorong and Wu, Lin and Shinno, Yuki and Daniele, Gennaro and Yang, Tsung-Ying and Kim, Hye Ryun and Ruiter, Gerrina and Zhao, Jun and Novello, Silvia and Miao, Liyun and Jänne, Pasi A and Goto, Koichi and Rüttinger, Dominik and Descamps, Tine and Brase, Jan Christoph and Bao, Weichao and Li, Rui and Brega, Nicoletta and Grassi, Paolo and Girard, Nicolas and Tan, Daniel Shao-Weng and SOHO-01 Investigators, SOHO-01 Investigators},
  title = {Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {18},
  pages = {1819--1832},
  doi = {10.1056/nejmoa2511065}
}
Kostenlos starten →